Previous close | 13.85 |
Open | 13.91 |
Bid | 14.11 x 400 |
Ask | 14.18 x 400 |
Day's range | 13.68 - 14.35 |
52-week range | 11.03 - 21.22 |
Volume | |
Avg. volume | 906,712 |
Market cap | 1.805B |
Beta (5Y monthly) | 1.10 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.70 |
Earnings date | 30 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 21.55 |
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FT. MYERS, Fla., April 18, 2024--NeoGenomics, Inc., announced two promotions within its senior leadership team, effective immediately.